Drug data last refreshed 28m ago · AI intelligence enriched 2w ago
ADAGEN (pegademase bovine) is a PEGylated adenosine deaminase enzyme replacement therapy administered by injection. It is indicated for adenosine deaminase (ADA) deficiency, a rare inherited metabolic disorder affecting immune system development. The drug works by replacing the missing or deficient ADA enzyme, allowing normal purine metabolism and immune reconstitution.
With LOE approaching and limited competitive pressure (30), this product likely operates as a niche specialty therapy with a small, specialized commercial team focused on rare disease expertise.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on ADAGEN offers deep expertise in orphan drug commercialization, rare disease patient management, and long-term lifecycle stewardship. This role suits professionals seeking meaningful impact in ultra-rare disease communities with smaller, highly specialized teams rather than broad commercial scale.
Worked on ADAGEN at Leadiant Biosciences? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.